Brain Network Analytics (BNA™)
FDA-cleared AI-powered neurological assessment platform combining EEG, ERP, and behavioral data
Platform · OtherCompany source
Company profile
About Firefly Neuroscience
Firefly Neuroscience is a medical equipment manufacturing company specializing in precision neuroscience through advanced AI-powered brain health assessments. The company's flagship FDA-cleared Brain Network Analytics (BNA™) platform utilizes an extensive proprietary EEG database to automatically analyze Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data. This comprehensive approach provides clinicians with objective, data-driven evaluations of brain function. The company's Evoke EEG/ERP platform serves psychiatry, neurology, and behavioral health practices, with particular applications in mental health conditions including ADHD and treatment-resistant depression. Firefly's technology enables clinicians to identify ideal candidates for treatments like Transcranial Magnetic Stimulation (TMS) and better understand non-responders through qEEG-guided approaches. Recently, Firefly expanded its offerings by partnering with NeuroSigma to distribute the Monarch eTNS System, the first FDA-cleared non-drug treatment for pediatric ADHD. This partnership addresses critical gaps in pediatric ADHD care by combining objective brain function data with non-medication treatment options. The company maintains a strong presence in the precision neuroscience space, conducting ongoing research to identify biomarkers for different ADHD presentations and other neurological conditions.
Company description Firefly Neuroscience official website
Primary marketMental Health & Digital Therapeutics
Commercial modelCommercial information available on request
Company presenceLinkedIn
Work at Firefly Neuroscience?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- ADHD
- Mental health disorders
- Neurological conditions
- Treatment-resistant depression
Who it serves
- Behavioral health practices
- Mental health clinics
- Neurology practices
- Psychiatry practices
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsCanada · Israel · United States
Company sourceOfficial website
Company milestones
Platform expansion
Partnership with NeuroSigma announced in 2024 to distribute Monarch eTNS System for pediatric ADHD; research published identifying biomarkers for ADHD presentations; expansion of qEEG-guided TMS applications
Partnerships
Recorded partners
- Deep Centered Mental Health
- NeuroSigma (Monarch eTNS System distribution)
- Radial
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Evoke EEG/ERP Platform
FDA-cleared EEG/ERP platform for psychiatry, neurology and behavioral health practices
Platform · OtherCompany source
Monarch eTNS System (Partnership)
First FDA-cleared non-drug treatment for pediatric ADHD using external trigeminal nerve stimulation
Device · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
The effects of deep TMS on purpose in life, quantitative EEG and event-related potentials in major depressive disorder.Applied neuropsychology. Adult · Jan 1, 2026
Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.Biomedicines · Jun 27, 2024
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Identification of TMS non-responders
qEEG analysis to optimize patient care and treatment selection
Objective brain function assessment
Data-driven evaluation for treatment planning in ADHD and depression
Deep Centered Mental Health
Offering TMS and SPRAVATO treatments for treatment-resistant depression in Houston
Emily Ahne Ph.D.
Using qEEG to identify TMS non-responders and optimize patient care
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Dave DeCaprio
Dr. Stella K. Vnook
Motti Kleinmann
Katie Murray
Michael P. Ward
06 · Company updates
Updates from Firefly Neuroscience
Recent articles published on Firefly Neuroscience's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Mental Health & Digital Therapeutics
Companies providing AI-powered mental health support, therapy platforms, mental wellness tracking, psychiatric care, digital therapeutics for mental health conditions, or AI-driven mental health screening and monitoring. Includes XR-based therapy, AI mental health screening infrastructure, and platforms supporting behavioral health for individuals and health systems.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.